ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in clinical trials. Here, we discuss the potential for e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Jette, Nicholas R., Kumar, Mehul, Radhamani, Suraj, Arthur, Greydon, Goutam, Siddhartha, Yip, Steven, Kolinsky, Michael, Williams, Gareth J., Bose, Pinaki, Lees-Miller, Susan P.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140103/
https://ncbi.nlm.nih.gov/pubmed/32183301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030687
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky